This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Asthma affects approximately 8% of the adult population and up to 20% of children in North America, Europe, and Australia. The majority of these patients have mild-to-moderate disease, which can be controlled with inhaled corticosteroids and an inhaled short acting B-adrenergic agonist. It is, however, estimated that about 5% to 10% of asthma patients have severe disease that does not respond to usual treatment modalities, including systemic corticosteroids. This group of patients is an important subset of asthma patients. For example, they suffer the greatest impairment of their lifestyle, and their disease has a profound impact on the health-care system as they use a disproportional amount of health-care costs. Furthermore minorities and women share this burden. Finally, this aspect of asthma is poorly understood, and thus there are major limitations to new therapeutics. The NIH/NHLBI has funded a group of 8 investigators, a Data Coordinating Center (DCC), and a Data Safety Monitoring Board (DSMB) under the Acronym SARP (Severe Asthma Research Program). We believe that severe asthma may be caused, in some patients, by a persistent respiratory infections with viruses, Mycoplasma pneumoniae, or Chlamydia pneumoniae, and that this will be more common in severe disease. To evaluate this hypothesis, a severe asthma population will be identified and compared to mild-to-moderate asthma and normal controls. The primary objective of these studies will be to determine whether evidence of a persistent respiratory infections is associated with severe asthma and results in greater limitation in airflow.
| Burgess-Hull, Albert J; Roberts, Linda J; Piper, Megan E et al. (2018) The social networks of smokers attempting to quit: An empirically derived and validated classification. Psychol Addict Behav 32:64-75 |
| Kelly, Elizabeth A; Esnault, Stephane; Liu, Lin Ying et al. (2017) Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma. Am J Respir Crit Care Med 196:1385-1395 |
| Shen, Zhong-Jian; Hu, Jie; Kashi, Venkatesh P et al. (2017) Epstein-Barr Virus-induced Gene 2 Mediates Allergen-induced Leukocyte Migration into Airways. Am J Respir Crit Care Med 195:1576-1585 |
| Anderson, Halie M; Lemanske Jr, Robert F; Evans, Michael D et al. (2017) Assessment of wheezing frequency and viral etiology on childhood and adolescent asthma risk. J Allergy Clin Immunol 139:692-694 |
| Gomez, Jose L; Yan, Xiting; Holm, Carole T et al. (2017) Characterisation of asthma subgroups associated with circulating YKL-40 levels. Eur Respir J 50: |
| Kelly, Elizabeth A; Esnault, Stephane; Johnson, Sean H et al. (2016) Human eosinophil activin A synthesis and mRNA stabilization are induced by the combination of IL-3 plus TNF. Immunol Cell Biol 94:701-8 |
| Bray, Bethany C; Smith, Rachel A; Piper, Megan E et al. (2016) Transitions in Smokers' Social Networks After Quit Attempts: A Latent Transition Analysis. Nicotine Tob Res 18:2243-2251 |
| Dougherty, Ryan J; Ellingson, Laura D; Schultz, Stephanie A et al. (2016) Meeting physical activity recommendations may be protective against temporal lobe atrophy in older adults at risk for Alzheimer's disease. Alzheimers Dement (Amst) 4:14-7 |
| Johansson, Mats W; Evans, Michael D; Crisafi, Gina M et al. (2016) Serum periostin is associated with type 2 immunity in severe asthma. J Allergy Clin Immunol 137:1904-1907.e2 |
| Kolesar, Jill M; Pomplun, Marcia; Havighurst, Tom et al. (2015) Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer. J Oncol Pharm Pract 21:128-31 |
Showing the most recent 10 out of 459 publications
